<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00203476</url>
  </required_header>
  <id_info>
    <org_study_id>TREAC Cholesterol Study</org_study_id>
    <secondary_id>TREAC Cholesterol Study</secondary_id>
    <nct_id>NCT00203476</nct_id>
  </id_info>
  <brief_title>A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction</brief_title>
  <official_title>A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tuscaloosa Research &amp; Education Advancement Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Society of Health-System Pharmacists Research and Education Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tuscaloosa Research &amp; Education Advancement Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare LDL reduction compared to baseline in patients using maximum tolerated HMG CoA
      Reductase inhibitor (statin) therapy with adjunctive therapy with ezetimibe, colestipol, or
      niacin. The patient's cardiovascular risks are assessed to determine if National Cholesterol
      Education Program's Adult Treatment Panel III (NCEP ATP III) guidelines for low density
      lipoprotein (LDL) reduction were achieved between the three groups. Secondary measures
      examine the safety issues with liver function test (LFT) monitoring and rhabdomyolysis.
      High-density lipoproteins (HDL) elevations are monitored between the three groups to
      determine efficacy as a secondary outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      : Patients with hyperlipidemia who sign consent and who are currently at maximum tolerated
      dose of a statin and are not meeting NCEP ATPIII treatment goals for LDL cholesterol are
      enrolled in 12-week open label, prospective trial. Patients are randomized into one of three
      groups to receive ezetimibe, niacin, or colestipol in addition to current statin therapy.
      Patients are titrated as tolerated to therapeutic doses of study medications (ezetimibe
      10mg/day, niacin 1500mg/day, and colestipol 20gm/day). At baseline, informed consent; a
      laboratory admission profile (Chem20); weight; height; blood pressure; concomitant
      medications; cholesterol medication history; and grapefruit juice consumption data are
      gathered. At weeks 6 and 12, patients have their cholesterol panels and liver function tests
      assessed. Patients are also interviewed regarding side effects (including rhabdomyolysis),
      tolerance, changes in concomitant medications, and grapefruit juice consumption, along with
      weight and blood pressure measurements.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL Goal Attainment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Each participant had his LDL goal calculated based on the NCEP ATPIII guidelines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LFT Elevation</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidents of Rhabdomyolysis</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL From Baseline to 12 Weeks.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hyperlipidemia</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Statin with Niacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Niacin dose range of 500-1500mg (average 888mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Statin with Colestipol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colestipol dose range 5-15gm (average 9.5gm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Statin with Ezitimibe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ezitimibe 10mg (average 10mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin</intervention_name>
    <arm_group_label>Statin with Niacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colestipol</intervention_name>
    <arm_group_label>Statin with Colestipol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <arm_group_label>Statin with Ezitimibe</arm_group_label>
    <other_name>Zetia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Veterans eligible for treatment at the Tuscaloosa VA Medical Center

          -  50 years of age

          -  Male or female

          -  Any race or ethnic group

          -  Signed informed consent

          -  Hyperlipidemia despite current maximum tolerated dose of an HMG CoA Reductase
             inhibitor (statin) for &gt; 6 weeks

          -  Currently not meeting NCEP ATPIII treatment goals for LDL cholesterol

        Exclusion Criteria:

          -  Known hypersensitivity or intolerance to ezetimibe, niacin, or colestipol

          -  Previous failed adequate trial of adjunctive ezetimibe, niacin, or colestipol

          -  Consumes more than 8oz. grapefruit juice daily

          -  Significant medical condition that would impact safety evaluations (i.e. significantly
             elevated LFT, hepatitis, severe dermatitis, uncontrolled diabetes, severe GI disease,
             fibromyalgia, renal failure, recent CVA or MI, pancreatitis, etc.)

          -  Receiving medications that would be contraindicated to use in combination with
             ezetimibe, niacin, or colestipol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raela B Williford, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tuscaloosa VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tuscaloosa Research &amp; Education Advancement Corporation</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ansell BJ. Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Curr Atheroscler Rep. 2005 Feb;7(1):29-33. Review.</citation>
    <PMID>15683599</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <results_first_submitted>December 5, 2013</results_first_submitted>
  <results_first_submitted_qc>August 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 12, 2014</results_first_posted>
  <last_update_submitted>August 8, 2014</last_update_submitted>
  <last_update_submitted_qc>August 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tuscaloosa Research &amp; Education Advancement Corporation</investigator_affiliation>
    <investigator_full_name>Raela Williford, PharmD</investigator_full_name>
    <investigator_title>Clinical Pharmacist/PI</investigator_title>
  </responsible_party>
  <keyword>ezetimibe</keyword>
  <keyword>niacin</keyword>
  <keyword>colestipol</keyword>
  <keyword>hyperlipidemia</keyword>
  <keyword>adjunct therapy</keyword>
  <keyword>zetia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Colestipol</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from 2005-2007 from primary care medical clinics.</recruitment_details>
      <pre_assignment_details>Patients had to be on max tolerated dose of a statin and need additional LDL lowering.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Niacin</title>
          <description>Niacin added to max tolerated dose of statin</description>
        </group>
        <group group_id="P2">
          <title>Colestipol</title>
          <description>Colestipol added to max dose statin</description>
        </group>
        <group group_id="P3">
          <title>Ezetimibe</title>
          <description>Ezetimibe added to max tolerated dose statin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>100% male, age 50 years or greater</population>
      <group_list>
        <group group_id="B1">
          <title>Niacin</title>
          <description>Niacin added to max tolerated dose of statin</description>
        </group>
        <group group_id="B2">
          <title>Colestipol</title>
          <description>Colestipol added to max dose statin</description>
        </group>
        <group group_id="B3">
          <title>Ezetimibe</title>
          <description>Ezetimibe added to max tolerated dose statin</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Age =&gt;50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>LDL Goal Attainment</title>
        <description>Each participant had his LDL goal calculated based on the NCEP ATPIII guidelines.</description>
        <time_frame>12 weeks</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin added to max tolerated dose of statin</description>
          </group>
          <group group_id="O2">
            <title>Colestipol</title>
            <description>Colestipol added to max dose statin</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe</title>
            <description>Ezetimibe added to max tolerated dose statin</description>
          </group>
        </group_list>
        <measure>
          <title>LDL Goal Attainment</title>
          <description>Each participant had his LDL goal calculated based on the NCEP ATPIII guidelines.</description>
          <population>intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LFT Elevation</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin added to max tolerated dose of statin</description>
          </group>
          <group group_id="O2">
            <title>Colestipol</title>
            <description>Colestipol added to max dose statin</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe</title>
            <description>Ezetimibe added to max tolerated dose statin</description>
          </group>
        </group_list>
        <measure>
          <title>LFT Elevation</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidents of Rhabdomyolysis</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin added to max tolerated dose of statin</description>
          </group>
          <group group_id="O2">
            <title>Colestipol</title>
            <description>Colestipol added to max dose statin</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe</title>
            <description>Ezetimibe added to max tolerated dose statin</description>
          </group>
        </group_list>
        <measure>
          <title>Incidents of Rhabdomyolysis</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="30.55"/>
                    <measurement group_id="O2" value="0" spread="12.97"/>
                    <measurement group_id="O3" value="0" spread="20.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HDL From Baseline to 12 Weeks.</title>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Change in HDL</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin</title>
            <description>Niacin added to max tolerated dose of statin</description>
          </group>
          <group group_id="O2">
            <title>Colestipol</title>
            <description>Colestipol added to max dose statin</description>
          </group>
          <group group_id="O3">
            <title>Ezetimibe</title>
            <description>Ezetimibe added to max tolerated dose statin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HDL From Baseline to 12 Weeks.</title>
          <population>Change in HDL</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.33" spread="11.20"/>
                    <measurement group_id="O2" value="39.22" spread="14.22"/>
                    <measurement group_id="O3" value="32.90" spread="5.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.00" spread="11.62"/>
                    <measurement group_id="O2" value="37.56" spread="7.83"/>
                    <measurement group_id="O3" value="34.70" spread="10.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Niacin</title>
          <description>Niacin added to max tolerated dose of statin</description>
        </group>
        <group group_id="E2">
          <title>Colestipol</title>
          <description>Colestipol added to max dose statin</description>
        </group>
        <group group_id="E3">
          <title>Ezetimibe</title>
          <description>Ezetimibe added to max tolerated dose statin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Indestion and belching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Loose Stools</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated LFTs</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>1 participant in the ezetimibe group had LFTs &gt;3 x upper limit of normal. All other elevated LFTs were not 3 x ULN.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Open label.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Raela Williford, PharmD</name_or_title>
      <organization>TuscaloosaREAC</organization>
      <phone>(205) 554-2000 ext 2433</phone>
      <email>Raela.Williford@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

